Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Halozyme Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: http://www.halozyme.com
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Helen I. Torley, MD
Number Of Employees: 350
Enterprise Value: $7,128,190,440
PE Ratio: 16.81
Exchange/Ticker 1: NASDAQ:HALO
Exchange/Ticker 2: N/A
Latest Market Cap: $7,127,854,080
BioCentury | Mar 25, 2025
Management Tracks
Warp Speed veteran Hepburn named EVP of R&D at Panther
Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Dec 4, 2024
Data Byte
Nine PDUFA dates on FDA’s December calendar
Ionis’ first wholly owned product among three rare disease therapies up for approval. BMS expecting decision on subcutaneous Opdivo
BioCentury | Nov 12, 2024
Deals
GHO, Ampersand to take Avid Bioservices private
BioCentury’s Deals report also includes Karalis’s public path via AlloVir reverse merger, and updates from Oblenio-Leads, Daiichi-Alteogen and Acadia
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
BioCentury | Oct 4, 2024
Data Byte
FDA’s September approvals include firsts for schizophrenia, Niemann-Pick
Subcutaneous formulations of Tecentriq and Ocrevus also among month’s seven new product approvals
BioCentury | Oct 20, 2023
Deals
Oct. 18 Quick Takes: Merck to pay $4B up front for three Daiichi ADCs
Plus: PTC reaps $1B from sale of Evrysdi royalties and updates from Sirius, BMS and Ultragenyx
BioCentury | Sep 20, 2023
Management Tracks
Rezo names Nazir Mahmood CEO
Plus: Bendtsen named CEO of Orphazyme, and updates from Acadia, OM1 and BioPorto
BioCentury | Sep 6, 2023
Data Byte
11 PDUFA dates on FDA’s agenda in September
Decisions due this month include BioLineRx’s Aphexda, Roche’s subcutaneous Tecentriq and GSK’s momelotinib
BioCentury | Jun 21, 2023
Deals
June 20 Quick Takes: FDA approves argenx’s subcutaneous Vyvgart
Plus: Clozel provides Idorsia cash lifeline, a clinical hold for Arcellx and updates from Vera, Denali, Delve Bio and Turbine
Items per page:
1 - 10 of 378